Explore 2025 biosimilar approval trends, regional bottlenecks, and why most applications fail despite rising global market demand.Read More
As we move deeper into 2025, biosimilars are gaining unprecedented traction.Read More
Biosimilars are near-identical versions of approved biologics, offering similar safety, efficacy, and quality—but at a lower cost. Unlike generics, biosimilars are made from living cells and require complex development and regulatory approval.Read More